Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:30:39 EDT Mon 09 Mar 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:VKTX - VIKING THERAPEUTICS INC - https://www.vikingtherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VKTX - Q2.533.00·33.981.033.61+0.631.91,933.663,22418,79132.87  33.7999  32.5143.15  18.9219:57:09Mar 0515 min RT 2¢

Recent Trades - Last 10 of 18791
Time ETExPriceChangeVolume
19:57:09Q33.77010.790110
19:46:46Q33.770.7923
19:46:31Q33.770.7918
19:46:25Q33.770.79150
19:42:20Q33.840.863
19:39:22Q33.520.5410
19:33:32Q33.520.5420
19:33:14Q33.510.5366
19:24:28Q33.510.531
19:21:17Q33.510.53110

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-03-05 16:03U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2026-02-11 16:05U:VKTXNews ReleaseViking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
2026-02-04 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
2026-01-12 07:00U:VKTXNews ReleaseViking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
2026-01-08 07:00U:VKTXNews ReleaseViking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
2026-01-07 07:00U:VKTXNews ReleaseViking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
2026-01-05 16:03U:VKTXNews ReleaseViking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-25 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
2025-11-19 02:55U:VKTXNews ReleaseViking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
2025-11-06 07:05U:VKTXNews ReleaseViking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek(TM) 2025
2025-11-04 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2025-10-29 16:05U:VKTXNews ReleaseViking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek(TM) 2025
2025-10-22 16:05U:VKTXNews ReleaseViking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-10-21 07:05U:VKTXNews ReleaseViking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
2025-10-15 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
2025-08-28 16:30U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2025-08-19 07:05U:VKTXNews ReleaseViking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
2025-07-23 16:05U:VKTXNews ReleaseViking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-07-16 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
2025-06-25 07:03U:VKTXNews ReleaseViking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735